Kamada Ltd(KMDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 22 at 7:30 PM ET (Korea 9/23 08:30)
Full metrics table
| Index | - | P/E | 23.24 | EPS (ttm) | 0.38 | Insider Own | 45.17% | Shs Outstand | 57.7M | Perf Week | 9.64% |
| Market Cap | 0.51B | Forward P/E | 14.87 | EPS next Y | 22.39% | Insider Trans | -0.76% | Shs Float | 31.7M | Perf Month | 7.65% |
| Enterprise Value | 0.45B | PEG | 0.64 | EPS next Q | 0.13 | Inst Own | 16.44% | Short Float | 0.5% | Perf Quarter | 24.4% |
| Income | 0.02B | P/S | 2.67 | EPS this Y | 33.69% | Inst Trans | -3.35% | Short Ratio | 1.48 | Perf Half Y | 8.17% |
| Sales | 0.19B | P/B | 1.9 | EPS next 5Y | 23.09% | ROA | 5.92% | Short Interest | 0.16M | Perf YTD | 25.64% |
| Book/sh | 4.67 | P/C | 7.3 | EPS past 3/5Y | - -2.03% | ROE | 8.4% | 52W High | -5.13% ($9.35) | Perf Year | 26.9% |
| Cash/sh | 1.22 | P/FCF | 18.53 | Sales past 3/5Y | 11.74% 6.25% | ROIC | 7.97% | 52W Low | 36.46% ($6.50) | Perf 3Y | 71.57% |
| Dividend Est. | $0.42 (4.74%) | EV/EBITDA | 10.51 | EPS Y/Y TTM | 16.67% | Gross Margin | 40.82% | Volatility(W/M) | 2.8% 2.65% | Perf 5Y | 67.04% |
| Dividend TTM | 0.42 | EV/Sales | 2.36 | Sales Y/Y TTM | 13.17% | Oper. Margin | 14.5% | ATR (14) | 0.26 | Perf 10Y | 79.19% |
| Dividend Ex-Date | 2026/8/27 | Quick Ratio | 2.29 | EPS Q/Q | 25.1% | Profit Margin | 11.6% | RSI (14) | 64.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.06 | Sales Q/Q | 22.72% | SMA20 | 5.9% ($8.38) | Beta | 0.91 | Target Price | $13.5 |
| Payout | 64.45% | Debt/Eq | 0.04 | Earnings | 2026/8/12 | SMA50 | 14.62% ($7.74) | Rel Volume | 1.19 | Prev Close | $8.74 |
| Employees | 462 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 53.24% 8.03% | SMA200 | 12.1% ($7.91) | Avg Volume(3M) | 0.11M | Price | $8.87 |
| IPO | 2013/5/31 | Option/Short | Yes/Yes | Trades | 1494 | Volume | 125,857 | Change | 1.49% |
Company
KMDA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global biopharmaceutical company that develops and manufactures plasma-derived specialty immunoglobulin and protein therapies. It maintains a marketed product portfolio targeting rare and serious diseases, and operates numerous plasma collection centers across the United States, establishing a vertically integrated business structure that spans from raw plasma sourcing to finished pharmaceuticals.
Over the past 1 year, on the higher side
5% below its 1-year high.
KMDA makes money exceptionally well
14.5% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +33.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at 23.2 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +71.6% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 4.74% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 16.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IZRL 0.02%
AIMS 0.00%
IBBQ 0.00%
BIB 0.00%
ISCF 0.00%It ranks #4 in the industry
Based on market cap of $512M.
KMDA $512M PER 23.2
TAK $60B PER -
TEVA $46B PER 65.9
HLN $41B PER 19.0
FAQ
What kind of company is KMDA?
KMDA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of KMDA?
The market cap of KMDA is approximately $512M, ranking 3,203 within its sector.
Does KMDA pay dividends?
KMDA has a dividend yield of approximately 4.74%, with an annual dividend of $0.42.
What is the P/E ratio of KMDA?
KMDA has a P/E ratio of approximately 23.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KMDA?
KMDA has recorded a 52-week high of $9.35 and a low of $6.50.
